LOXL2 and ovarian cancer: One study documented that treatment with the LOXL2‐neutralizing antibody AB0023 in ovarian cancer mice contributed to the normalization of cancer vessels and increased the perfusion of cancer‐related vessels, thus facilitating the delivery of chemotherapeutic drugs into cancers and enhancing the chemotherapeutic efficiency.56